PT2999714T - Moléculas de ligação que se ligam ao fator c2 do complemento humano e suas utilizações - Google Patents

Moléculas de ligação que se ligam ao fator c2 do complemento humano e suas utilizações

Info

Publication number: PT2999714T
Authority: PT; Portugal
Prior art keywords: binding molecules; complement factor; human complement; bind human; bind
Prior art date: 2013-05-23

Application number

PT147294631T

Other languages

English (en)

Original Assignee

Broteio Pharma B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-05-23

Filing date

2014-05-22

Publication date

2020-04-30

2014-05-22 Application filed by Broteio Pharma B V filed Critical Broteio Pharma B V

2020-04-30 Publication of PT2999714T publication Critical patent/PT2999714T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PT147294631T 2013-05-23 2014-05-22 Moléculas de ligação que se ligam ao fator c2 do complemento humano e suas utilizações PT2999714T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP13168941		2013-05-23

Publications (1)

Publication Number	Publication Date
PT2999714T true PT2999714T (pt)	2020-04-30

Family

ID=48485015

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT201651650T PT3725803T (pt)	2013-05-23	2014-05-22	Moléculas de ligação que se ligam ao fator c2b do complemento humano e suas utilizações
PT147294631T PT2999714T (pt)	2013-05-23	2014-05-22	Moléculas de ligação que se ligam ao fator c2 do complemento humano e suas utilizações

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT201651650T PT3725803T (pt)	2013-05-23	2014-05-22	Moléculas de ligação que se ligam ao fator c2b do complemento humano e suas utilizações

Country Status (14)

Country	Link
US (2)	US9944717B2 (pt)
EP (2)	EP3725803B1 (pt)
JP (3)	JP2016520313A (pt)
CN (1)	CN105492461B (pt)
AU (1)	AU2014269193C1 (pt)
CA (1)	CA2913318C (pt)
DK (2)	DK3725803T3 (pt)
ES (2)	ES2904709T3 (pt)
HU (2)	HUE049769T2 (pt)
LT (2)	LT2999714T (pt)
MX (1)	MX366046B (pt)
PL (2)	PL2999714T3 (pt)
PT (2)	PT3725803T (pt)
WO (1)	WO2014189378A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2914291T3 (pl)	2012-11-02	2022-10-03	Bioverativ Usa Inc.	Przeciwciała anty-C1s dopełniacza i ich zastosowania
US9944717B2 (en) *	2013-05-23	2018-04-17	Broteio Pharma B.V.	Binding molecules that bind human complement factor C2 and uses thereof
EP4652926A3 (en)	2016-10-12	2026-03-18	Bioverativ USA Inc.	Anti-c1s antibodies and methods of use thereof
LT3893924T (lt)	2018-12-13	2024-10-10	argenx BV	Antikūnai žmogaus komplemento faktoriui c2b ir jų panaudojimo būdai
GB2584105B (en)	2019-05-21	2023-08-02	Argenx Bvba	Methods of treating neuropathy
AU2020330307A1 (en) *	2019-08-12	2022-03-17	CSL Innovation Pty Ltd	Complement C2 binding proteins and uses thereof
EP4469475A1 (en) *	2022-01-29	2024-12-04	Kira Pharmaceuticals (Suzhou) Ltd.	Anti-c2 antibodies and uses thereof
GB202407051D0 (en)	2024-05-17	2024-07-03	argenx BV	Methods of treating osteoarthritis pain
WO2025257157A1 (en)	2024-06-10	2025-12-18	argenx BV	Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) *	2024-06-17	2025-12-26	CSL Innovation Pty Ltd	Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
PT1265929E (pt)	2000-03-23	2009-10-15	Genentech Inc	Inibidores anti-c2/c2a de activação complementar
US9944717B2 (en)	2013-05-23	2018-04-17	Broteio Pharma B.V.	Binding molecules that bind human complement factor C2 and uses thereof

2014
- 2014-05-22 US US14/892,850 patent/US9944717B2/en active Active
- 2014-05-22 AU AU2014269193A patent/AU2014269193C1/en active Active
- 2014-05-22 DK DK20165165.0T patent/DK3725803T3/da active
- 2014-05-22 PT PT201651650T patent/PT3725803T/pt unknown
- 2014-05-22 HU HUE14729463A patent/HUE049769T2/hu unknown
- 2014-05-22 PL PL14729463T patent/PL2999714T3/pl unknown
- 2014-05-22 JP JP2016515304A patent/JP2016520313A/ja active Pending
- 2014-05-22 ES ES20165165T patent/ES2904709T3/es active Active
- 2014-05-22 PT PT147294631T patent/PT2999714T/pt unknown
- 2014-05-22 DK DK14729463.1T patent/DK2999714T3/da active
- 2014-05-22 HU HUE20165165A patent/HUE057858T2/hu unknown
- 2014-05-22 ES ES14729463T patent/ES2784616T3/es active Active
- 2014-05-22 WO PCT/NL2014/050327 patent/WO2014189378A1/en not_active Ceased
- 2014-05-22 CN CN201480042146.0A patent/CN105492461B/zh active Active
- 2014-05-22 EP EP20165165.0A patent/EP3725803B1/en active Active
- 2014-05-22 LT LTEP14729463.1T patent/LT2999714T/lt unknown
- 2014-05-22 CA CA2913318A patent/CA2913318C/en active Active
- 2014-05-22 EP EP14729463.1A patent/EP2999714B1/en active Active
- 2014-05-22 MX MX2015016120A patent/MX366046B/es active IP Right Grant
- 2014-05-22 LT LTEP20165165.0T patent/LT3725803T/lt unknown
- 2014-05-22 PL PL20165165T patent/PL3725803T3/pl unknown
2018
- 2018-02-23 US US15/903,810 patent/US10717785B2/en active Active
2019
- 2019-08-13 JP JP2019148550A patent/JP7163254B2/ja active Active
2022
- 2022-10-19 JP JP2022167816A patent/JP7414929B2/ja active Active

Also Published As

Publication number	Publication date
HK1223385A1 (zh)	2017-07-28
EP3725803A1 (en)	2020-10-21
LT2999714T (lt)	2020-07-10
ES2784616T3 (es)	2020-09-29
US10717785B2 (en)	2020-07-21
PL2999714T3 (pl)	2020-10-19
LT3725803T (lt)	2022-03-10
US20180319895A1 (en)	2018-11-08
AU2014269193C1 (en)	2020-02-20
HUE057858T2 (hu)	2022-06-28
CA2913318C (en)	2024-03-26
MX366046B (es)	2019-06-26
JP2016520313A (ja)	2016-07-14
AU2014269193B2 (en)	2019-08-15
DK3725803T3 (da)	2022-03-07
JP2020007318A (ja)	2020-01-16
CN105492461B (zh)	2019-11-26
HUE049769T2 (hu)	2020-10-28
AU2014269193A1 (en)	2015-12-17
PT3725803T (pt)	2021-12-24
MX2015016120A (es)	2016-10-28
ES2904709T3 (es)	2022-04-05
WO2014189378A1 (en)	2014-11-27
CA2913318A1 (en)	2014-11-27
CN105492461A (zh)	2016-04-13
EP2999714B1 (en)	2020-04-01
DK2999714T3 (da)	2020-06-02
JP7163254B2 (ja)	2022-10-31
US20160108134A1 (en)	2016-04-21
EP3725803B1 (en)	2021-12-15
JP7414929B2 (ja)	2024-01-16
PL3725803T3 (pl)	2022-04-04
JP2023002684A (ja)	2023-01-10
EP2999714A1 (en)	2016-03-30
US9944717B2 (en)	2018-04-17

Publication	Publication Date	Title
ZA201505209B (en)	2019-07-31	Binding molecules for bcma and cd3
IL254223A (en)	2017-10-31	CD20 binding compounds and their uses
IL240045A0 (en)	2015-08-31	Antigen-binding molecules activate bi-specific t cells
IL240838A0 (en)	2015-10-29	Anti-3–lag binding proteins
HUE049769T2 (hu)	2020-10-28	Humán komplemens C2 faktort kötõ kötõ molekulák és alkalmazásaik
SG11201505762XA (en)	2015-08-28	Il-11r binding proteins and uses thereof
SG11201509260RA (en)	2015-12-30	Chimeric fvii-xten molecules and uses thereof
SG11201600275PA (en)	2016-02-26	Novel adsorbent composition and use thereof
PT3077467T (pt)	2022-12-19	Composição desidratante e a respetiva utilização
ZA201506186B (en)	2016-11-30	Ligand binding molecules and uses thereof
SI3072905T1 (sl)	2020-12-31	IL-17A-vezavno sredstvo in uporabe le-tega
ZA201507808B (en)	2017-02-22	Binding element
HUE056609T2 (hu)	2022-02-28	NOTCH1-re specifikus SIRNS-molekulák
GB201306588D0 (en)	2013-05-29	Peptides and Binding Partners Therefor
ZA201503962B (en)	2016-07-27	Fines binding process and binding composition thereof
HU4488U (en)	2015-01-28	Plaster-coated and edge-protected chipboard
GB201314294D0 (en)	2013-09-25	Binding surfaces